Sign in
Taking peopleNo phase

Looking back at heart valve disease care across South Korea over 10 years

Reviews past heart ultrasound and medical records of people with moderate or severe valve disease.

Key facts

Who runs it
Yonsei University
Where
South Korea2 sites in 1 countryChoose a country to see its sites
Trial code
Registry title
Korea VHD Echo Study: Surveillance of Aortic, Mitral & Tricuspid Patients - Insights From Real-world Practice
Status
Recruiting
People taking part
30,000 people, planned
Started
22 Sept 2025
Expected to end
31 Dec 2027
Type of study
Observational, 3 groups
Record updated
30 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with moderate or severe disease of their own heart valves. It looks back at records and heart ultrasound scans from 2010.1.1 to 2020.12.31.

Age
Older than 18 years (from 19 Years).
Sex
All sexes can join.
Disease stage
Moderate or severe disease of the person's own (native) heart valve: narrowing of the aortic valve (AS), leaking aortic valve (AR), leaking mitral valve (MR) or leaking tricuspid valve (TR).
Earlier treatment
People must have had a heart ultrasound (echocardiography) more than twice.

Main reasons for not taking part

  • Poor quality heart ultrasound images
  • Lost to follow-up

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Period: 2010.1.1~2020.12.31
  • Age > 18 years
  • Moderate or severe native VHD (AS, AR, MR and TR)
  • Perform echocardiography more than twice

Who cannot take part

  • Poor image of echocardiography
  • Follow up loss

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Valvular heart disease (VHD) is a growing public health concern globally, with increasing disease burden and rising interest in advanced treatment strategies such as transcatheter interventions. However, there remains a significant lack of real-world data regarding echocardiography practices, disease prevalence and progression, referral patterns, and treatment pathways. Addressing these gaps is critical for improving patient care and informing clinical decision-making.

Read full original descriptionShow less

South Korea provides a unique opportunity to conduct a nationwide retrospective echocardiographic study due to its advanced healthcare infrastructure, high patient volume, and strong tradition in clinical research. The current study aims to evaluate the real-world burden and clinical journey of patients with moderate or severe valvular disease over a 10-year period, based on echocardiographic and electronic medical record (EMR) data collected from multiple tertiary centers across the country.

The 3 groups in the trial

  • Aortic petients

    Primary focus is aortic stenosis patients; secondary focus is aortic regurgitation.

  • Mitral Patients

    Primary focus is Degenerative Mitral Regurgitation patients; secondary focus is Functional Mitral Regurgitation.

  • Tricuspid Patients

    Primary focus is Tircuspid Regurgitation patients

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Korea VHD Echo Study: Surveillance of Aortic, Mitral & Tricuspid Patients - Insights From Real-world Practice
Plain-language title
Looking back at heart valve disease care across South Korea over 10 yearsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
30 October 2026